Form 4: Dogwood Therapeutics Director Thomas John C Granted 420 Stock Options
Insider Transaction Report
Dogwood Therapeutics, Inc. Director Thomas John C was granted 420 stock options with an exercise price of $4.80 per share, exercisable starting June 18, 2026, and expiring on June 18, 2035.
Summary
- Thomas John C, a Director of Dogwood Therapeutics, Inc. (DWTX), acquired stock options.
- The transaction occurred on June 18, 2025.
- A total of 420 stock options were acquired.
- Each option has an exercise price of $4.80.
- These options become exercisable on June 18, 2026, and expire on June 18, 2035.
- The options represent the right to buy 420 shares of Dogwood Therapeutics Common Stock.
- The reporting person now directly beneficially owns 420 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns their interests with shareholders and signals confidence in the company's future, although it's a grant, not an open market purchase.
Positives
- A director acquiring stock options can signal confidence in the company's future performance.
- The options align the director's interests with those of shareholders, as their value increases with the stock price.
Industry Context
This is a routine insider transaction filing. It indicates standard equity compensation practices for directors within the biotechnology or pharmaceutical industry, aligning management incentives with shareholder value.
Related Party Transactions
- The acquisition of stock options by a director is a related party transaction, as it involves an insider of the company.
Stakeholder Impact
- Shareholders: The grant of options to a director can be seen as a positive signal, indicating management's belief in future stock price appreciation. It also aligns the director's financial incentives with shareholder returns.
Key Dates
| Date | Description |
|---|---|
| 06/18/2025 | Date of earliest transaction (acquisition of stock options) |
| 06/18/2026 | Date stock options become exercisable |
| 06/18/2035 | Expiration date of stock options |
| 06/23/2025 | Date the Form 4 was filed |
Recommendation
holdKeywords
Dogwood Therapeutics, DWTX, SEC Form 4, insider trading, stock options, director, beneficial ownership, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.